CA3243960A1 - RHO KINASE INHIBITION COMPOSITIONS AND METHODS - Google Patents

RHO KINASE INHIBITION COMPOSITIONS AND METHODS

Info

Publication number
CA3243960A1
CA3243960A1 CA3243960A CA3243960A CA3243960A1 CA 3243960 A1 CA3243960 A1 CA 3243960A1 CA 3243960 A CA3243960 A CA 3243960A CA 3243960 A CA3243960 A CA 3243960A CA 3243960 A1 CA3243960 A1 CA 3243960A1
Authority
CA
Canada
Prior art keywords
cancer
larazotide
subject
derivative
rock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3243960A
Other languages
English (en)
French (fr)
Inventor
Younggeon JIN
Nir Barak
Jain KIM
Original Assignee
Interlude Biopharma Co
University of Maryland, College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interlude Biopharma Co, University of Maryland, College Park filed Critical Interlude Biopharma Co
Publication of CA3243960A1 publication Critical patent/CA3243960A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3243960A 2022-02-09 2023-02-09 RHO KINASE INHIBITION COMPOSITIONS AND METHODS Pending CA3243960A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308330P 2022-02-09 2022-02-09
US63/308,330 2022-02-09
PCT/US2023/062247 WO2023154770A1 (en) 2022-02-09 2023-02-09 Compositions and methods for inhibiting rho kinase

Publications (1)

Publication Number Publication Date
CA3243960A1 true CA3243960A1 (en) 2023-08-17

Family

ID=87565095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3243960A Pending CA3243960A1 (en) 2022-02-09 2023-02-09 RHO KINASE INHIBITION COMPOSITIONS AND METHODS

Country Status (6)

Country Link
US (1) US20250144166A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475867A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506487A (cg-RX-API-DMAC7.html)
CN (1) CN119730867A (cg-RX-API-DMAC7.html)
CA (1) CA3243960A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118873629B (zh) * 2024-09-27 2024-12-10 北京大学口腔医学院 醋酸拉唑肽在制备促进成骨药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047532A2 (en) * 2007-10-12 2009-04-16 Cancer Research Technology Limited Cancer susceptibility loci
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP2020507626A (ja) * 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法
WO2019183036A1 (en) * 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
KR20220049005A (ko) * 2019-08-16 2022-04-20 9 미터스 바이오파마, 인코포레이티드 라라조타이드 제형
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids

Also Published As

Publication number Publication date
WO2023154770A1 (en) 2023-08-17
EP4475867A1 (en) 2024-12-18
JP2025506487A (ja) 2025-03-11
EP4475867A4 (en) 2026-02-18
US20250144166A1 (en) 2025-05-08
CN119730867A (zh) 2025-03-28

Similar Documents

Publication Publication Date Title
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
US12059397B2 (en) Calcium lactate compositions and methods of use
RU2016127232A (ru) Антисмысловые композиции и способы их получения и применения
TR201905226T4 (tr) Bir gecikmeli salım ilaç formülasyonu.
KR20170029576A (ko) 골형성단백질의 치료적 용도
CN121943909A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
US20260034191A1 (en) Larazotide formulations
US20250144166A1 (en) Compositions and methods for inhibiting rho kinase
WO2023114984A1 (en) Tead inhibitors and uses thereof
MG Saez Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer
Zhang et al. The ACE2 activator diminazene aceturate ameliorates colitis by repairing the gut-vascular barrier in mice
JP7502832B2 (ja) 膵癌細胞の浸潤転移抑制剤
JP2013537221A (ja) 改良された経口標的化薬物送達システム
CN115956078A (zh) Akt3调节剂及其使用方法
CN116390757A (zh) 用于治疗肿瘤的药物组合物
KR20230005209A (ko) D-아미노산을 포함하는 라라조타이드 유도체
EP4489756A1 (en) Methods of treating small cell lung cancer
CN121548414A (zh) Hippo-yap通路调节剂的药物制剂和给药日程
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
CN118217382A (zh) 使用麦胶蛋白肽治疗癌症的套件和方法
Dayanc et al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue
WO2017095826A1 (en) Combination therapy for treatment of melanoma
Dayanc et al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is
Zhao et al. Zolbetuximab combined with chemotherapy in a patient with CLDN18. 2-positive advanced gastric cancer undergoing hemodialysis: a case report
Hao et al. Breaking the'Undruggable'Barrier: Nanoparticle-Based Combination Therapy Utilizing Sotorasib and PD-L1 Inhibitor for Treating Non-Small Cell Lung Cancer Patients with KRASG12C Mutations

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240809

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240812

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240812

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250205

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250207

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260127